CA
NZ
UK
AU
IND
US
● Nutex Health swung to second-quarter 2026Net Incomeof $65.8 million and diluted EPS of $9.38, from a $17.7 million loss a year earlier, even asRevenuefell 13.6% to $210.8 million after a HaloMD billing-partner amendment and lower federal arbitration fees.
TheNasdaqComposite is broad enough to hold almost every Nasdaq-listed common stock, which means it also holds the small and mid-cap biotech names where the market's real drug-development risk lives. uniQure (NASDAQ:QURE), Xencor (NASDAQ:XNCR), Rani Therapeutics (NASDAQ:RANI), Pyxis Oncology (NASDAQ:PYXS) and Precision BioSciences (NASDAQ:DTIL) span …
● SpyGlass Pharma reported 12-month Phase 1/2 results showing a 34% mean reduction in intraocular pressure from its BIM-IOL glaucoma lens system, with $251.0 million in cash and runway guided through 2028.
● SELLAS Life Sciences is approaching the pre-specified 80th event in its pivotal Phase 3 REGAL trial for galinpepimut-S in acute myeloid leukemia, with roughly $138.3 million in cash as of June 30, 2026.
● Spruce Biosciences reported $96.3 million in cash as of June 30, 2026, and plans to submit aBiologicsLicense Application for TA-ERT in MPS IIIB (Sanfilippo Syndrome Type B) in the fourth quarter of 2026.
September 2026 is a useful moment to look at healthcare on theNasdaqComposite because the month bunches together the parts of the sector that rarely move on the same clock. A clinical-stage biotech is turning into a commercial one. A diagnostics company is trying to …
Biotech and health technology rarely move as one, and September 2026 is a useful reminder of why. Within theNasdaqComposite sit hundreds of life-science names spanning pre-revenue clinical bets and cash-generating device businesses, and the gap between the two ends of that spectrum has seldom …
● Astrana Health reported second-quarterRevenueof $972.5 million, up 49% year over year, and raised full-year 2026 guidance to revenue of $4.1 billion and adjusted EBITDA of $280 million.
Biotech and health technology rarely move as a single block, and that is exactly the point. As of mid-September 2026, theNasdaqComposite houses companies at every stage of the healthcare life cycle, from profitable commercial franchises to pre-revenue clinical developers burning cash toward a first …
Biotech rarely moves as a single block, and this quintet proves it. Grouped only by their Nasdaq listing and their place in health innovation, CG Oncology (NASDAQ:CGON), Pasithea Therapeutics (NASDAQ:KTTA), GRAIL (NASDAQ:GRAL), AbCelleraBiologics(NASDAQ:ABCL) and Belite Bio (NASDAQ:BLTE) sit at wildly different points on the …
Please wait processing your request...